News Join our mailing list to receive our quarterly email newsletter with news, updates and events in bowel management. SUBSCRIBE AllCancerCoeliac DiseaseConstipationIncontinenceIBSInflammatory Bowel DiseasePaediatricsLilly reports positive data from its ulcerative colitis phase 3 trialApril 12, 2021Pembrolizumab added to NHSE COVID interim treatment list for colorectal cancerApril 6, 2021NICE recommends andexanet alfa (ONDEXXYA®▼) for uncontrolled bleeds in the gastrointestinal tractApril 6, 2021GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancersJanuary 18, 2021New data show positive association between Remsima® SC pre-dose level with efficacy outcomesOctober 14, 2020Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s DiseaseOctober 14, 2020Sandoz announces positive NICE recommendation for Rizmoic® (naldemedine) for OIC.September 30, 2020Treatment for men with enlarged prostate is recommended by NICE for NHS adoptionSeptember 11, 2020Roche provide update on phase III studies of etrolizumab in people with ulcerative colitisAugust 10, 2020European Commission grants marketing authorisation for Remsima® SC in Crohn’s disease & ulcerative colitis.July 27, 2020New study into link between IBD and colorectal cancersJuly 22, 2020The BSG issues interim guidance for diagnosing coeliac disease without biopsyJuly 13, 20204 12345678 5
NICE recommends andexanet alfa (ONDEXXYA®▼) for uncontrolled bleeds in the gastrointestinal tractApril 6, 2021
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancersJanuary 18, 2021
New data show positive association between Remsima® SC pre-dose level with efficacy outcomesOctober 14, 2020
Interim Results Released from Phase 2 Study on TREMFYA®▼ (guselkumab) in Patients with Crohn’s DiseaseOctober 14, 2020
Roche provide update on phase III studies of etrolizumab in people with ulcerative colitisAugust 10, 2020
European Commission grants marketing authorisation for Remsima® SC in Crohn’s disease & ulcerative colitis.July 27, 2020
